Clinical Trials Browser

Phase 1/2 × Terminated × ixazomib × Clear all

NCT02898259 2022-09-26

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Phase 1/2 Terminated

19 enrolled 15 charts

Lymphoma, Lymphoma, B-Cell

NCT02993094 2020-11-30

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms